US 12,269,792 B2
Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate
Adam Galan, Alameda, CA (US); Ritu Lal, Palo Alto, CA (US); and Wendy Luo, Palo Alto, CA (US)
Assigned to GENIE LIFESCIENCES INC., Palo Alto, CA (US)
Filed by GEN1E LIFESCIENCES INC., Palo Alto, CA (US)
Filed on May 12, 2022, as Appl. No. 17/743,035.
Application 17/743,035 is a continuation of application No. 17/506,822, filed on Oct. 21, 2021, granted, now 11,390,581.
Claims priority of provisional application 63/106,991, filed on Oct. 29, 2020.
Prior Publication US 2022/0267259 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 311/29 (2006.01)
CPC C07C 311/29 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
 
1. A compound, crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide:

OG Complex Work Unit Chemistry
wherein the compound is characterized by an X-ray powder diffraction (XRPD) pattern comprising characteristic diffraction peaks at least at 13.1°±0.2°, 14.6°±0.2°, 15.0°±0.2°, 18.1±0.2°, 22.2±0.2°, 22.6±0.2°, and 24.4±0.2° expressed as 2θ angles and determined using Cu-Kα radiation.